![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
ABSTRACT
The association between polymorphism of CC chemokine ligand 5 (CCL5) and cancer has been reported in several studies, however, there is no data in papillary thyroid cancer (PTC). Objectives: The aim of this study was to investigate whether a promoter single nucleotide polymorphisms (SNP) in CCL5 contributes to the development of PTC and assess the relationships between the CCL5 SNP and the cliniopathologic characteristics of PTC. Methods: One promoter SNP (rs2107538, –281C/T) in CCL5 was genotyped using direct sequencing in 93 PTC patients and 212 healthy controls. Genetic data were analyzed using SNPStats, Helixtree, and SNPAnalyzer. PTC patients were dichotomized and compared with respect to cliniopathologic characteristics of PTC. Results: An association was evident between PTC and SNP (rs2107538) in CCL5 [codominant model 2 (T/T vs. C/C), OR = 2.74, 95% CI = 1.18–6.37, p = .019; dominant model, OR = 2.25, 95% CI = 1.01–5.03, p = .049; recessive model, OR = 1.73, 95% CI = 1.06–2.82, p = .030]. When the genetic relationships between SNP and subgroups of PTC patients were assessed, SNP rs2107538 in CCL5 was not associated with any clinicopathologic characteristics of PTC. Conclusions: SNP in the CCL5 -281 promoter gene could increase the risk of developing PTC in Koreans.